Anticoagulant versus antiplatelet treatment for secondary stroke prevention in patients with active cancer

Approximately 5-10% of patients with acute ischemic stroke (AIS) have known active cancer. These patients are at high risk for both recurrent AIS and major bleeding. The optimal antithrombotic strategy for cancer-related stroke is uncertain. This study compared clinical outcomes among patients with...

Celý popis

Podrobná bibliografie

Vydáno v:	Frontiers in neurology Ročník 16; s. 1530775
Hlavní autoři:	Kielkopf, Moritz C., Göcmen, Jayan, Venzin, Selina B., Steinauer, Fabienne, Branca, Mattia, Boronylo, Anna, Göldlin, Martina B., Kaesmacher, Johannes, Mujanovic, Adnan, Costamagna, Gianluca, Meinel, Thomas R., Seiffge, David J., Bücke, Philipp, Heldner, Mirjam R., Liberman, Ava L., Kamel, Hooman, Fischer, Urs, Arnold, Marcel, Pabst, Thomas, Berger, Martin D., Jung, Simon, Scutelnic, Adrian, Navi, Babak B., Beyeler, Morin
Médium:	Journal Article
Jazyk:	angličtina
Vydáno:	Switzerland Frontiers Media S.A 2025
Témata:	acute ischemic stroke antithrombotic drugs cancer embolic stroke of unknown source (ESUS) secondary prevention cancer secondary prevention antithrombotic drugs embolic stroke of unknown source (ESUS) acute ischemic stroke
ISSN:	1664-2295, 1664-2295
On-line přístup:	Získat plný text
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!